0000000000086284

AUTHOR

Frederico Cappuzzo

showing 2 related works from this author

Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the s…

2015

Oncologymedicine.medical_specialtybusiness.industryHistologySubgroup analysisHematologyPlaceboStage IV non-small cell lung cancerSurgeryRamucirumabDouble blindSecond lineOncologyDocetaxelInternal medicinemedicinebusinessmedicine.drug
researchProduct

The role of research nurse in translational studies: LUCAS experience

2015

medicine.medical_specialtyOncologyNursingbusiness.industryAlternative medicineMedicineHematologybusinessAnnals of Oncology
researchProduct